Product
Supplier
Encyclopedia
Inquiry
Home > Active Pharmaceutical Ingredients > Other Chemical Drugs > Tirzepatide for Sale > Tirzepatide USFDA approved injection grade
Tirzepatide USFDA approved injection grade buy - large image1
Tirzepatide USFDA approved injection grade buy - image1
Tirzepatide USFDA approved injection grade buy - image2

Tirzepatide USFDA approved injection grade

GMP ISO FDA 2099 Inquiries

Unit Price: Get Latest Price
CAS No.:

2023788-19-2

Content:

99%

Port:

Hangzhou

Packaging:

5mg/vial,10mg/vial,1gram/vial, 10gram/vial;100gram/bag

Price valid (until):

2025-02-07

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,100% TT in advance
Average Lead Time:
10 days
Qualification:
Main Products:

Semaglutide,Tirzepatide,Retatrutide,Melanotan,Melatonine,Coenzyme Q10

  • Product Details

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Tirzepatide is a weekly dual agonist of glucose dependent insulinotropic peptide (GIP) receptor and glucagon like peptide-1 (GLP-1) receptor developed by Eli Lilly. GIP and GLP-1 are both hormones secreted by the intestine, which can promote insulin secretion. Tirzepatide integrates two insulin promoting effects into a single molecule, representing a new class of drugs for the treatment of type 2 diabetes. Tirzepatide has a similar sequence to semaglutide, and the lys side chain in the sequence is modified with PEG, which is a functional group of peptides and can increase the water solubility of the sequence. The main physiological function of Tirzepatide is glucose dependent insulin nutritional polypeptide (GIP) and glucagon like peptide-1 (GLP-1) receptor dual agonist, which is being developed for the treatment of type 2 diabetes and has entered the clinical stage.

    Items Specifications






    ECHEMI Editorial Reference

    Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

    Certificates

    Basic Info
    Product Name:

    Tirzepatide

    Other Name:

    LY3298176;

    CAS No.:

    2023788-19-2

    Molecular Formula:

    C225H348N48O68

    Molecular Weight:

    4813

    EC Number:

    200-001-8

    Categories:

    Other Chemical Drugs

    Characteristics
    Appearance:

    White to off-white

    Research
    Class:

    Dual agonist — GIPR, GLP-1R

    Status:

    FDA-approved (Mounjaro / Zepbound)

    Mechanism:

    Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.

    EC50 (Human GLP1R):

    0.934 nM

    EC50 (Human GIPR):

    0.0224 nM

    Source:

    Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI

    FDA:

    Mounjaro, Zepbound (approved 2022-05-13)

    References
    ChEMBL:

    CHEMBL4297839

    DrugBank:

    DB15171

    KEGG DRUG:

    D11360

    PubChem:

    PubChem

    Disclaimer:

    Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Semaglutide,Tirzepatide,Retatrutide,Melanotan,Melatonine,Coenzyme Q10

    Location:

    Building 1, No.15, Xingling Str., Xingqiao Str., Linping Dist., Hangzhou, China

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,100% TT in advance

    Average lead Time:

    10 days

    Total Annual Revenue:

    $5 million-$10 million

    Total Employees:

    101-200

    Year of Establishment:

    2014

    Deepharma, founded in 2014 by a group of professionals from fortune 500 with many years of experience, is a dynamically developing high-tech pharmaceutical enterprise of production and distribution of ingredient substances and dietary supplements. In spite of the 10 years' young age for the pharmaceutical industry, we has already filled a niche on the domestic and abroad market and continues to expand it.

    We are eager to bring added value and constant search for better solutions. Cooperating with CPU and ZJUT graduate school and other institutes, it brings continuously power to innovate in R&D process. We would keep introducing new technology and latest product to make lives better.


    All these products have been specifically formulated for particular health and sector needs.
    Key areas of expertise are:
    Custom peptides;
    Anti-aging peptides;
    Whitening peptides;
    Antioxidant;
    Sleep aid and etc.
    Products are either API, cosmetic ingredients or food supplements by registration category. Most are ready with GMP, DMF, ISO and TDS. Welcome to your cooperation!
  • Inquiry History
    2099 Inquiries
    Country Product Purchase Quantity Date Posted
    Philippines

    Tirzepatide

    2 MT Oct 27, 2026
    Philippines

    Tirzepatide

    30 MG Oct 26, 2026
    Slovakia

    Tirzepatide

    1 G Oct 26, 2026
    France

    Tirzepatide

    1 KG Oct 25, 2026
    United States

    Tirzepatide

    2.5 MG Oct 25, 2026
    United Kingdom

    Tirzepatide

    5 MT Oct 25, 2026
    United Kingdom

    Tirzepatide

    6 MT Oct 24, 2026
    Peru

    tirzepatide

    10 MG Oct 21, 2026
    Puerto Rico

    tirzepatide

    40 MG Oct 21, 2026
    United States

    Tirzepatide

    10 MT Oct 21, 2026
    South Africa

    Tirzepatide

    1 MT Oct 20, 2026
    United States

    Tirzepatide

    5 KG Oct 20, 2026
    United States

    tirzepatide

    30 MG Oct 20, 2026
    United States

    Tirzepatide

    50 MG Oct 20, 2026
    Spain

    tirzepatide

    20 MG Oct 19, 2026
    United States

    tirzepatide

    30 MG Oct 19, 2026
    Philippines

    tirzepatide

    40 MG Oct 19, 2026
    United States

    tirzepatide

    50 MG Oct 19, 2026
    United States

    tirzepatide

    50 MG Oct 19, 2026
    United States

    Tirzepatide

    20 MG Oct 19, 2026
    Post an enquiry for this product

More from this Seller

pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.